RNA Atrium Therapeutics, Inc.

8.260USD+4.16%Mkt Cap: 141.29M $P/E: —

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stag…

Key Statistics

Company
Market Cap141.29M USD
Enterprise Value-125.54M USD
Revenue (TTM)35.84M USD
Gross Profit-20.20M USD
Net Income (TTM)-76.68M USD
Revenue/Share2.10 USD
Last Price8.260 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.99
PEG—
EV/EBITDA1.83
EV/Revenue-3.50
P/S3.81
P/B0.64
EPS (TTM)-5.44
EPS (Forward)-8.06
52W Range
7.6307% of range16.77
52W High16.77 USD
52W Low7.630 USD
Profitability
Gross Margin-56.37%
Oper. Margin-752.93%
EBITDA Margin-191.22%
Profit Margin-411.88%
ROE-36.99%
ROA-27.55%
Growth
Revenue Growth-21.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-41.13M USD
CapEx (TTM)1.45M USD
FCF Margin—
FCF Yield—
Net Debt-262.22M USD
Net Debt/EBITDA3.83
Balance Sheet
Debt/Equity0.02
Current Ratio8.73
Quick Ratio8.38
Book Value/Sh12.54 USD
Cash/Share15.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)25.00 USD
Upside (mean)+202.7%
Target Range25.00 USD – 25.00 USD
# Analysts4
Ownership
Shares Out.17.11M
Float15.04M
Insiders4.16%
Institutions84.56%
Short Interest
Short Ratio11.6d
Short % Out.19.86%
Shares Short3.40M
Short (prev mo.)3.48M
Technical
SMA 5011.33 (-27.1%)
SMA 20012.58 (-34.3%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)373.43K
Avg Vol (10d)331.06K
Technical Indicators
RSI (14)32.4
MACD-0.9811
MACD Signal-1.0484
MACD Hist.+0.0673
BB Upper10.39 USD
BB Middle8.757 USD
BB Lower7.126 USD
BB Width37.24%
ATR (14)0.5049 USD
Vol Ratio (20d)1.36x